Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Price Target at $25.83

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $25.83.

A number of equities research analysts have recently commented on the stock. BMO Capital Markets upped their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a report on Monday, September 16th. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. Oppenheimer reiterated an "outperform" rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a "buy" rating and a $33.00 price target on the stock. Finally, Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th.

Centessa Pharmaceuticals Stock Performance

CNTA traded up $0.17 on Tuesday, reaching $17.12. The company had a trading volume of 510,468 shares, compared to its average volume of 418,422. Centessa Pharmaceuticals has a 1 year low of $6.15 and a 1 year high of $18.74. The stock has a market capitalization of $2.26 billion, a PE ratio of -11.19 and a beta of 1.52. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average price of $16.25 and a 200-day moving average price of $12.78.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. As a group, research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 175,000 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the transaction, the chief executive officer now owns 776,924 shares in the company, valued at approximately $12,834,784.48. This represents a 18.38 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 16,619 shares of the company's stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the completion of the transaction, the insider now owns 206,750 shares in the company, valued at approximately $3,243,907.50. This represents a 7.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 375,128 shares of company stock worth $6,148,522 over the last 90 days. 11.59% of the stock is owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CNTA. First Light Asset Management LLC grew its position in Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock worth $43,168,000 after acquiring an additional 1,778,515 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock worth $18,024,000 after buying an additional 1,625,000 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth $20,698,000. Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after buying an additional 1,145,823 shares during the period. Finally, Driehaus Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock worth $18,891,000 after buying an additional 987,997 shares during the period. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.